InspireMD (NSPR) Price & Analysis

Compare

696 Followers

NSPR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.99 - $3.80

Previous CloseN/A

Volume8.46K

Average Volume (3M)91.47K

Market Cap

$100.55M

Enterprise Value$99.83M

Total Cash (Recent Filing)$19.37M

Total Debt (Recent Filing)$3.42M

Price to Earnings (P/E)―

Beta-0.11

Next Earnings

Nov 11, 2025

EPS Estimate

-0.2

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.26

Shares Outstanding41,720,660

10 Day Avg. Volume64,761

30 Day Avg. Volume91,465

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.99

Enterprise Value/Revenue14.13

Enterprise Value/Gross Profit67.09

Enterprise Value/Ebitda-2.38

Forecast

1Y Price Target

$3.83

Price Target Upside61.60% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Acquisition PotentialInspireMD could be an attractive add-on for Boston or other big MedTech cardiovascular players.

Analyst RecommendationAnalyst recommends a Buy rating and a $5 price target.

Business GrowthInspireMD can quickly build a $50M CGuard business and a $25M SwitchGuard business by 2028.

Market ShareBest-in-class data should result in fast share taking for InspireMD's CGuard.

Product PerformanceThe 30-day DSMI rate for CGuard is sub-1% vs. others from 2.3% to as high as 8.3%, supporting a quick share shift within the TF-CAS market.

Regulatory ApprovalInspireMD is approaching its most important catalyst, FDA approval of its CGuard carotid artery stent.

Bears Say

InspireMD News

InspireMD files to sell 16.56M shares of common stock for holders

16:08 EDT InspireMD (NSPR) files to sell 16.56M shares of common stock for holders Published first on TheFly...

17d ago

NSPR

InspireMD reports Q2 EPS (26c) vs (22c) last year

Reports Q2 revenue $1.778M vs $1.739M last year. Marvin Slosman, CEO of InspireMD (NSPR), commented: “Over the last...

18d ago

NSPR

InspireMD appoints Raymond Cohen to board of directors

InspireMD (NSPR) announced the appointment of Raymond W. Cohen to its Board of Directors. Until May of 2025,...

23d ago

NSPR

InspireMD announces combined financings of $58M

InspireMD (NSPR) announced the Company has raised approximately $58 million in combined gross proceeds through an equity private...

23d ago

NSPR

InspireMD Inc. Navigates Trade Policy Risks with U.S. Manufacturing Plans

InspireMD Inc (NSPR) has disclosed a new risk, in the Capital Markets category. InspireMD Inc. faces significant business...

17d ago

NSPR

InspireMD Inc. Reports Q2 2025 Earnings and Regulatory Milestones

InspireMD Inc ( ($NSPR) ) has released its Q2 earnings. Here is a breakdown of the information InspireMD...

17d ago

NSPR

InspireMD’s Earnings Call: FDA Approval and Financial Challenges

InspireMD Inc (($NSPR)) has held its Q2 earnings call. Read on for the main highlights of the call....

18d ago

NSPR

InspireMD Reports Q2 2025 Financial Results and Milestones

An update from InspireMD ( ($NSPR) ) is now available. On August 5, 2025, InspireMD reported its financial...

18d ago

NSPR

InspireMD Inc (NSPR) Q2 Earnings Cheat Sheet

InspireMD Inc (NSPR) is scheduled to report 2nd quarter earnings on 08/05/2025, before the market opens. Regarding Q2...

20d ago

NSPR

InspireMD Raises $40.1M in Private Placement Offering

InspireMD ( ($NSPR) ) just unveiled an update. On July 30, 2025, InspireMD entered into a securities purchase...

23d ago

NSPR

InspireMD Launches CGuard Prime Stent in U.S. Market

InspireMD ( ($NSPR) ) has provided an update. On July 9, 2025, InspireMD announced the U.S. commercial launch...

2M ago

NSPR

InspireMD announces commercial launch of the CGuard Prime in the U.S.

InspireMD (NSPR) announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following...

2M ago

NSPR

InspireMD Gains FDA Approval for CGuard Stent System

InspireMD ( ($NSPR) ) just unveiled an announcement. On June 23, 2025, InspireMD announced that the FDA granted...

2M ago

NSPR

Inspire Medical granted premarket application approval for CGuard Prime

Inspire Medical announced that the FDA has granted premarket application approval of the CGuard Prime Carotid Stent System...

2M ago

NSPR

NSPR FAQ

What was InspireMD Inc’s price range in the past 12 months?

InspireMD Inc lowest stock price was $1.99 and its highest was $3.80 in the past 12 months.

What is InspireMD Inc’s market cap?

InspireMD Inc’s market cap is $100.55M.

When is InspireMD Inc’s upcoming earnings report date?

InspireMD Inc’s upcoming earnings report date is Nov 11, 2025 which is in 80 days.

How were InspireMD Inc’s earnings last quarter?

InspireMD Inc released its earnings results on Aug 05, 2025. The company reported -$0.26 earnings per share for the quarter, the consensus estimate of -$0.26 by $0.

Is InspireMD Inc overvalued?

According to Wall Street analysts InspireMD Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does InspireMD Inc pay dividends?

InspireMD Inc does not currently pay dividends.

What is InspireMD Inc’s EPS estimate?

InspireMD Inc’s EPS estimate is -0.2.

How many shares outstanding does InspireMD Inc have?

InspireMD Inc has 41,720,660 shares outstanding.

What happened to InspireMD Inc’s price movement after its last earnings report?

InspireMD Inc reported an EPS of -$0.26 in its last earnings report, expectations of -$0.26. Following the earnings report the stock price went down -8.24%.

Which hedge fund is a major shareholder of InspireMD Inc?

Currently, no hedge funds are holding shares in NSPR

InspireMD Stock Smart Score

Outperform

Fundamentals

Return on Equity

-123.51%

Trailing 12-Months

Asset Growth

-40.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

InspireMD Inc

InspireMD, Inc., a medical device company, focuses on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of vascular and coronary diseases in Europe, Latin America, the Middle East, and Asia Pacific. The company offers CGuard carotid embolic prevention system for use in carotid artery applications; and MGuard Prime embolic protection systems for use in patients with acute coronary syndromes, notably acute myocardial infarction, and saphenous vein graft coronary interventions, as well as bypass surgery. It is also developing PVGuard, a MicroNet mesh sleeve and self-expandable stent for use in peripheral vascular applications. The company sells its products through local distributors. InspireMD, Inc. was founded in 2005 and is headquartered in Tel Aviv-Yafo, Israel.

InspireMD (NSPR) Earnings & Revenues

Historic Earnings Reports

NSPR Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant achievements, including FDA approval and strong market reception for CGuard Prime, alongside successful financing efforts. However, financial challenges such as decreased gross profit, increased operating expenses, and a delay in product launch were also noted.View all NSPR earnings summaries

NSPR Stock 12 Month Forecast

Average Price Target

$3.83

▲(61.60% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","2.25":"$2.25","3.5":"$3.5","4.75":"$4.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$5.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.83,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":2.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$2.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,2.25,3.5,4.75,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.8676923076923075,3.0453846153846156,3.223076923076923,3.4007692307692308,3.5784615384615384,3.756153846153846,3.933846153846154,4.111538461538462,4.28923076923077,4.466923076923077,4.644615384615385,4.822307692307692,{"y":5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.7776923076923077,2.8653846153846154,2.953076923076923,3.040769230769231,3.1284615384615386,3.216153846153846,3.3038461538461537,3.3915384615384614,3.479230769230769,3.566923076923077,3.6546153846153846,3.7423076923076923,{"y":3.83,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.69,2.6753846153846155,2.6607692307692306,2.646153846153846,2.6315384615384616,2.6169230769230767,2.602307692307692,2.5876923076923077,2.5730769230769233,2.5584615384615383,2.543846153846154,2.5292307692307694,2.5146153846153845,{"y":2.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.34,"date":1690848000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.75,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.48,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.05,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.63,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.6,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.54,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.23,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.69,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >